Pharmaceutical preparations
Definition
SIC 2834, pharmaceutical preparations.
A standard grouping: SIC 2834.
Q2 2026 against Q1 2026
- Reported value
- $510bn
- +$47.1bn on the quarter before
- Managers listing any
- 64
- +2 on the quarter before
- Stocks listed
- 236
- +4 on the quarter before
- Buyers
- 2,873
- manager-stock pairs opening or adding
- Sellers
- 2,597
- manager-stock pairs trimming or exiting
value over 8 quartersNet buying actions by quarter: +166 · +138 · +177 · +169 · +173 · +719 · +406 · +276
See it in the heatmap, ranked by breadth →
Managers listing any counts distinct comparable managers. Buyers and sellers count actions by comparable managers, once for each stock a manager moved in. Value moves with prices as well as with buying.
Largest stocks (236 in all)
By combined reported value at Q2 2026. Holders are at least counts, among listed positions.
| Stock | Holders | Value | Buyers | Sellers | Holders, 8 quarters |
|---|---|---|---|---|---|
| LLYEli Lilly & Co | 47 | $132bn | 24 | 24 | |
| JNJJohnson & Johnson | 39 | $39.4bn | 18 | 21 | |
| VRTXVertex Pharmaceuticals Inc | 35 | $34.7bn | 21 | 17 | |
| ABBVAbbvie Inc | 39 | $33.5bn | 24 | 16 | |
| MRKMerck & Co Inc | 36 | $29.6bn | 14 | 24 | |
| AZNAstrazeneca PLC | 33 | $29.1bn | 19 | 18 | |
| ALNYAlnylam Pharmaceuticals Inc | 34 | $16.2bn | 17 | 18 | |
| ABTAbbott Laboratories | 42 | $16.0bn | 23 | 21 | |
| REGNRegeneron Pharmaceuticals | 35 | $11.4bn | 24 | 15 | |
| BMYBristol-myers Squibb Co | 34 | $8.4bn | 15 | 23 | |
| GSKGSK PLC | 25 | $7.7bn | 15 | 12 | |
| PFEPfizer Inc | 34 | $6.0bn | 20 | 16 | |
| IONSIonis Pharmaceuticals Inc | 30 | $5.8bn | 13 | 19 | |
| BBIOBridgebio Pharma Inc | 35 | $5.4bn | 24 | 15 | |
| ROIVRoivant Sciences LTD | 32 | $5.4bn | 20 | 11 | |
| INSMInsmed Inc | 35 | $5.3bn | 28 | 11 | |
| ASNDAscendis Pharma A | 27 | $4.7bn | 19 | 9 | |
| UTHRUnited Therapeutics Corp Del | 34 | $4.6bn | 19 | 16 | |
| RPRXRoyalty Pharma PLC | 36 | $4.4bn | 21 | 17 | |
| ELANElanco Animal Health Inc | 29 | $4.0bn | 15 | 15 | |
| VTRSViatris Inc | 32 | $3.7bn | 12 | 23 | |
| NVONovo-nordisk A S | 30 | $3.6bn | 13 | 18 | |
| ZTSZoetis Inc | 40 | $3.3bn | 27 | 14 | |
| MDGLMadrigal Pharmaceuticals Inc | 31 | $3.0bn | 18 | 15 | |
| PRAXPraxis Precision Medicines I | 25 | $2.7bn | 17 | 8 |
Managers holding its largest names
Across the 15 largest stocks above at Q2 2026: how many of them each manager lists, and their combined value. A manager can hold others below its listed range.
- Fidelity (FMR LLC)12 of 15 · $72.0bn
- Capital World Investors10 of 15 · $52.6bn
- Capital Research Global Investors10 of 15 · $51.8bn
- Wellington Management Group LLP14 of 15 · $42.9bn
- T. Rowe Price Associates Inc13 of 15 · $38.8bn
- Invesco Ltd11 of 15 · $24.5bn
- Janus Henderson Group Ltd13 of 15 · $13.7bn
- AllianceBernstein LP11 of 15 · $11.4bn
- AQR Capital Management LLC11 of 15 · $7.4bn
- MFS Investment Management9 of 15 · $7.0bn
- Dodge & Cox11 of 15 · $6.2bn
- Neuberger Berman Group LLC10 of 15 · $5.5bn
- Arrowstreet Capital LP10 of 15 · $4.5bn
- Citadel Advisors LLC7 of 15 · $3.9bn
- Acadian Asset Management LLC11 of 15 · $3.7bn
- Two Sigma Investments LP9 of 15 · $3.4bn
- Marshall Wace LLP8 of 15 · $3.0bn
- D. E. Shaw & Co.10 of 15 · $2.8bn
- Man Group PLC11 of 15 · $2.1bn
- Harris Associates LP3 of 15 · $1.6bn